Highest-materiality recent filing
Daré Bioscience receives Nasdaq delisting notice for equity deficiency; plans to request hearing
Nasdaq notified Daré on July 13, 2026 that stockholders' equity was below $2.5M as of March 31, 2026.
Dare Bioscience furnishes corporate presentation; content not provided in filing
Corporate presentation dated July 13, 2026 furnished as Exhibit 99.1 under Item 7.01.
Daré Bioscience furnishes corporate presentation for investor meetings on June 22, 2026
Presentation available in the Investors section of company website.
Daré Bioscience stockholders approve 1.5M share increase in 2022 plan and ratify auditor
Stockholders approved amendment to 2022 Stock Incentive Plan adding 1,500,000 shares; total reserve becomes 2,883,333 shares.
Daré Bioscience closes Reg A offering, raises $250K from 50,000 units at $5/unit
Issued 50,000 Investor Units at $5.00 each, total gross proceeds $250,000.
Daré Bioscience reports Q1 2026 cash $18.5M; first product revenue expected June 2026
Cash and equivalents $18.5M as of March 31; working capital ~$0.5M; revenue $0.2M from Gates Foundation services.
Daré Bioscience closes $975k Regulation A offering of Series A Preferred and warrants
Issued 195,010 Investor Units at $5.00 each, each unit consisting of one Series A Preferred share and two common stock warrants.
Daré Bioscience posts updated corporate presentation on investor website
Presentation dated April 22, 2026, furnished as Exhibit 99.1.
Daré Bioscience closes $100K Reg A offering of 20,000 units at $5/unit
Issued 20,000 Investor Units, each: one share Series A Convertible Preferred + two warrants for common stock.
Gregory W. Matz reclassified from Class II to Class III director to rebalance board classes
Matz resigned as Class II director and was reappointed as Class III director effective April 16, 2026.
Daré Bioscience closes Reg A offering, issues 3,470 units at $5.00 each
Closed on April 10, 2026: issued 3,470 Investor Units, each at $5.00, for gross proceeds of $17,350.
Daré Bioscience FY2025: $24.7M cash, $20.8M equity proceeds; DARE to PLAY revenue expected Q2 2026
Cash and cash equivalents $24.7M at Dec 31, 2025; working capital $3.4M.
Daré Bioscience closes $215K Regulation A offering of Series A Preferred Stock and warrants
Issued 43,050 Investor Units at $5.00/unit; each unit contains one share of Series A Convertible Preferred and two common stock purchase warrants.
Daré Bioscience closes second tranche of Regulation A offering, issuing 17,500 units at $5.00
Issued 17,500 Investor Units at $5.00 each, raising $87,500 in gross proceeds.
Daré Bioscience posts updated corporate presentation; no specific details in filing
Updated corporate presentation made available on company website on March 2, 2026.
Daré Bioscience closes initial tranche of Reg A offering at $5/unit; issues 5,090 units
Initial closing on Jan 27, 2026: issued 5,090 Units (each 1 share Series A Preferred + 2 warrants) for $25,450 gross proceeds.
Daré Bioscience posts updated corporate presentation; no material new info disclosed
Filed under Item 7.01; presentation available on company website and as Exhibit 99.1.
Bayer terminates Ovaprene license; Daré regains full rights, Phase 3 study continues
Bayer HealthCare terminated Ovaprene license agreement effective Feb 24, 2026 due to strategic prioritization.
DARE Bioscience reports Q3 cash $23.1M; Sildenafil Cream on track for Dec launch via 503B
Cash and equivalents $23.1M; working capital $3.8M as of Sep 30, 2025.
Daré Bioscience provides corporate presentation; no specific data disclosed
Presentation dated September 2, 2025 filed as exhibit; full content not included in 8-K.
Cash of $5.0M at June 30; working capital deficit $12.6M; raised ~$17.6M net from ATM and $6M grant post-quarter.
Daré Bioscience regains Nasdaq compliance but faces one-year Mandatory Panel Monitor
Received Nasdaq letter confirming compliance with stockholders' equity rule (Nasdaq 5550(b)(1)) on July 24, 2025.
Dare Bioscience raises $16.5M, believes it regains Nasdaq equity compliance
Raised approx. $16.5M gross from ATM and equity line sales since Mar 31, 2025.
Daré's Ovaprene Phase 3 interim shows ~9% pregnancy rate; DSMB OK to continue
DSMB recommended study continue without modification after planned interim safety analysis.
Dare Bioscience shareholders approve 600,000-share increase to 2022 stock plan; re-elect directors
Stockholders re-elected directors Matz, Rastetter, and Steele; each received >2.4M votes for.
Nasdaq panel approves Dare Bioscience's compliance plan; deadline Aug 12, 2025
Panel approved modified plan to regain compliance with Nasdaq Listing Rules 5550(b)(1) (≥$2.5M equity) or 5550(b)(2) (≥$35M MVLS).
Dare Bioscience provides corporate presentation; filing text lacks specific content
Corporate presentation dated June 9, 2025 furnished as Exhibit 99.1.
Daré Bioscience Q1 2025: Cash $10.3M, R&D down 31%, expects first revenue in Q4 2025
Cash and equivalents $10.3M at March 31, 2025; working capital deficit of $9.4M.
Nasdaq grants Daré extension until Aug 12, 2025 to regain listing compliance
Extension conditional on meeting stockholders' equity >$2.5M by April 30, 2025 and further increase by July 15, 2025.
Dare Bioscience reports FY2024 cash $15.7M, plans Sildenafil Cream 503B launch in Q4 2025
Cash and equivalents $15.7M at Dec 31, 2024; working capital deficit of $3.2M.
Dare Bioscience receives Nasdaq delisting notice for failing to meet $35M minimum MVLS rule
On Feb 13, 2025, Nasdaq notified Dare Bioscience that its common stock is subject to delisting for failure to regain compliance with the Minimum MVLS Rule by Feb 10, 2025.
Presentation dated February 10, 2025, used at BIO CEO & Investor Conference in New York.
Dare Bioscience furnishes corporate presentation; specific details unavailable
Corporate presentation dated January 13, 2025 furnished under Item 7.01.
Daré announces Phase 3 plans for Sildenafil Cream for FSAD; protocol submission in Q1 2025
Will submit Phase 3 protocol and statistical plan to FDA in Q1 2025; target mid-2025 to start the study.
Daré Bioscience Q3 2024: cash $11.2M; grants up to $10.7M and $10M; pipeline advancing
Cash and equivalents $11.2M at Sept 30, 2024; R&D expenses fell 60% YoY to $2.7M; G&A $2.0M.
Daré Bioscience makes corporate presentation available to investors
Company filed a corporate presentation dated October 25, 2024 as Exhibit 99.1.
Daré Bioscience awarded $10M from ARPA-H to develop HPV treatment candidate DARE-HPV
Award of $10M from ARPA-H Sprint for Women's Health; milestone-based payments over 24 months.
Daré Bioscience secures $15M common stock purchase facility with Lincoln Park Capital
Entered $15M common stock purchase agreement with Lincoln Park Capital Fund, LLC.
Dare Bioscience Q2 cash $16.4M; Ovaprene Phase 3 enrolling; Sildenafil Cream awaits FDA feedback
Cash and equivalents $16.4M at June 30, 2024; received $22M non-dilutive royalty financing from XOMA in April 2024.
Daré regains Nasdaq minimum bid price compliance, delisting risk removed
Nasdaq notified Daré that closing bid price was ≥$1.00 for 10 consecutive sessions; compliance achieved.
1-for-12 reverse stock split effective July 1, 2024; shares reduce from ~101.1M to ~8.4M.
Re-elected directors Jessica D. Grossman, M.D. (28,626,331 for) and Susan L. Kelley, M.D. (28,623,481 for) as Class I directors.
Daré Bioscience Q1 cash $3.6M, secures $22M royalty financing; Ovaprene Phase 3 ongoing
Cash & equivalents $3.6M at March 31, 2024; subsequent $22M non-dilutive royalty financing from XOMA and $1M grant installment.
XOMA paid $22M upfront for 100% of Daré's net XACIATO royalties and milestones (after deductions); Daré also sold minority interest in Ovaprene/Sildenafil future revenue.
Net loss of $30.1M for FY2023; revenue of $2.8M from XACIATO milestone payments.
Dare Bioscience announces CFO retirement, CCO resignation, board downsizing
CFO Lisa Walters-Hoffert retired effective Jan. 26, 2024; will consult for 9 months at $31,667/month.
Dare Bioscience receives Nasdaq delisting notice for bid price below $1.00 per share
Received Nasdaq delisting notice on Jan 17, 2024 for failing to meet minimum $1.00 bid price requirement.
Filing under Item 7.01 discloses a corporate presentation dated January 8, 2024, used in investor meetings.
Dare Bioscience secures up to $12M royalty-backed financing; $5M upfront, warrants issued
Sold right to receive future royalty payments on XACIATO to United in Endeavour, LLC for up to $12M; $5M received at closing.
Dare Bioscience reports positive Phase 1 topline results for DARE-PDM1 in primary dysmenorrhea
DARE-PDM1 (vaginal diclofenac hydrogel) was well-tolerated; no serious AEs; 85% of AEs mild.
On January 24, 2024, John Fair, our Chief Commercial Officer, informed us that, in light of the full-scale commercial launch of XACIATO TM —bringing to fruition one of his primary responsibilities as Chief Commercial Officer—he will be resigning from all positions with us and his employment with us will end effective June 30, 2024.
Ms. Haring-Layton, our current Vice President, Accounting & Finance, was appointed as our Chief Accounting Officer and will serve as our principal accounting officer.
On January 23, 2024, Lisa Walters-Hoffert informed Daré Bioscience, Inc. (“our,” “we”, “us,” “our,” or the “Company”) that she will retire from all positions with the Company, and her employment with the Company will end, effective January 26, 2024.
Ms. Johnson, our Chief Executive Officer and President, will serve as our principal financial officer
Max materiality 0.80 · Median 0.60 · Most common event other_material